80/100B160.420
USD
-2.88
(-1.76%)
Pre Open
Last updated: · Delayed 15 min
Fair value128.72Plus+25%103Price 160.42634
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Q4 FY2026 · Earnings report
EPS estimate 2.23Revenue estimate 14.65B
Novartis price to sales (P/S) ratioWhat is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
Novartis's P/S ratio is 5.38: its market cap of 302.97B USD over revenue of 56.31B USD in the last twelve months.
- Today
- 5.38
- Average, 5 years
- 4.22
- Low, 5 years
- 2.94
- High, 5 years
- 5.75
P/S ratio = market cap ÷ revenue (last 12 months) = 302.97B ÷ 56.31B = 5.38
Each day's market cap over the revenue of the last four quarters reported by that day.
P/S ratio by year and by quarter
| Fiscal year | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Today | 5.38 | 302.97B | 56.31B | |
| FY2025 | 31 Dec 2025 | 4.88 | 267.32B | 54.81B |
| FY2024 | 31 Dec 2024 | 3.80 | 196.40B | 51.72B |
| FY2023 | 31 Dec 2023 | 4.49 | 209.69B | 46.66B |
| FY2022 | 31 Dec 2022 | 4.31 | 187.25B | 43.46B |
| FY2021 | 31 Dec 2021 | 4.22 | 185.62B | 43.97B |
| FY2020 | 31 Dec 2020 | 4.08 | 203.48B | 49.90B |
| FY2019 | 31 Dec 2019 | 4.22 | 205.26B | 48.68B |
| FY2018 | 31 Dec 2018 | 3.61 | 166.50B | 46.10B |
| FY2017 | 31 Dec 2017 | 3.80 | 164.79B | 43.40B |
| FY2016 | 31 Dec 2016 | 2.93 | 144.94B | 49.44B |
| FY2015 | 31 Dec 2015 | 3.43 | 172.98B | 50.39B |
| FY2014 | 31 Dec 2014 | 3.51 | 188.06B | 53.63B |
| FY2013 | 31 Dec 2013 | 3.11 | 164.16B | 52.72B |
| FY2012 | 31 Dec 2012 | 2.46 | 128.06B | 51.97B |
| FY2011 | 31 Dec 2011 | 1.92 | 113.93B | 59.38B |
| FY2010 | 31 Dec 2010 | 2.19 | 112.75B | 51.56B |
| FY2009 | 31 Dec 2009 | 2.29 | 103.28B | 45.10B |
| FY2008 | 31 Dec 2008 | 2.21 | 94.31B | 42.58B |
| FY2007 | 31 Dec 2007 | 2.70 | 105.31B | 38.95B |
| FY2006 | 31 Dec 2006 | 3.21 | 112.71B | 35.11B |
| FY2005 | 31 Dec 2005 | 3.44 | 102.43B | 29.75B |
| FY2004 | 31 Dec 2004 | 3.65 | 99.59B | 27.28B |
| FY2003 | 31 Dec 2003 | 3.67 | 91.37B | 24.93B |
| FY2002 | 31 Dec 2002 | 3.70 | 77.30B | 20.88B |
| FY2001 | 31 Dec 2001 | 4.19 | 78.54B | 18.76B |
| FY2000 | 31 Dec 2000 | 4.44 | 98.55B | 22.19B |
| FY1999 | 31 Dec 1999 | 3.85 | 78.56B | 20.39B |
| FY1998 | 31 Dec 1998 | 4.76 | 109.68B | 23.04B |
| Quarter | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 4.80 | 270.31B | 56.31B |
| Q2 FY2026 | 30 Jun 2026 | 5.37 | 298.55B | 55.63B |
| Q1 FY2026 | 31 Mar 2026 | 5.20 | 291.60B | 56.05B |
| Q4 FY2025 | 31 Dec 2025 | 4.70 | 263.75B | 56.15B |
| Q3 FY2025 | 29 Sept 2025 | 4.24 | 239.02B | 56.37B |
| Q2 FY2025 | 30 Jun 2025 | 4.27 | 235.73B | 55.19B |
| Q1 FY2025 | 31 Mar 2025 | 4.12 | 219.39B | 53.22B |
| Q4 FY2024 | 31 Dec 2024 | 3.74 | 193.35B | 51.72B |
| Q3 FY2024 | 30 Sept 2024 | 4.63 | 231.42B | 49.94B |
| Q2 FY2024 | 30 Jun 2024 | 4.43 | 216.60B | 48.86B |
| Q1 FY2024 | 31 Mar 2024 | 4.11 | 195.96B | 47.73B |
| Q4 FY2023 | 31 Dec 2023 | 4.44 | 206.99B | 46.66B |
| Q3 FY2023 | 30 Sept 2023 | 4.14 | 198.76B | 47.97B |
| Q2 FY2023 | 30 Jun 2023 | 4.26 | 198.91B | 46.66B |
| Q1 FY2023 | 31 Mar 2023 | 3.83 | 183.70B | 48.00B |
| Q4 FY2022 | 31 Dec 2022 | 3.68 | 183.29B | 49.77B |
| Q3 FY2022 | 30 Sept 2022 | 3.10 | 155.87B | 50.20B |
| Q2 FY2022 | 30 Jun 2022 | 3.33 | 175.82B | 52.79B |
| Q1 FY2022 | 31 Mar 2022 | 3.49 | 184.76B | 53.00B |
| Q4 FY2021 | 31 Dec 2021 | 3.50 | 185.16B | 52.88B |
| Q3 FY2021 | 30 Sept 2021 | 3.30 | 173.12B | 52.39B |
| Q2 FY2021 | 30 Jun 2021 | 3.76 | 193.66B | 51.56B |
| Q1 FY2021 | 31 Mar 2021 | 3.65 | 182.16B | 49.88B |
| Q4 FY2020 | 31 Dec 2020 | 4.06 | 202.40B | 49.90B |
| Q3 FY2020 | 30 Sept 2020 | 3.79 | 188.03B | 49.58B |
| Q2 FY2020 | 30 Jun 2020 | 3.82 | 189.19B | 49.53B |
| Q1 FY2020 | 31 Mar 2020 | 3.55 | 177.50B | 49.93B |
| Q4 FY2019 | 31 Dec 2019 | 4.17 | 202.94B | 48.68B |
| Q3 FY2019 | 30 Sept 2019 | 3.76 | 186.83B | 49.63B |
| Q2 FY2019 | 30 Jun 2019 | 4.14 | 200.79B | 48.53B |
| Q1 FY2019 | 31 Mar 2019 | 3.85 | 185.63B | 48.16B |
| Q4 FY2018 | 31 Dec 2018 | 3.46 | 165.83B | 47.87B |
| Q3 FY2018 | 30 Sept 2018 | 3.53 | 167.21B | 47.37B |
| Q2 FY2018 | 30 Jun 2018 | 3.02 | 147.07B | 48.67B |
| Q1 FY2018 | 31 Mar 2018 | 3.18 | 157.33B | 49.51B |
| Q4 FY2017 | 31 Dec 2017 | 3.25 | 163.12B | 50.14B |
| Q3 FY2017 | 30 Sept 2017 | 3.38 | 167.72B | 49.58B |
| Q2 FY2017 | 30 Jun 2017 | 3.34 | 164.40B | 49.23B |
| Q1 FY2017 | 31 Mar 2017 | 2.98 | 147.40B | 49.41B |
| Q4 FY2016 | 31 Dec 2016 | 2.93 | 144.73B | 49.44B |
| Q3 FY2016 | 30 Sept 2016 | 3.17 | 157.16B | 49.63B |
| Q2 FY2016 | 30 Jun 2016 | 3.30 | 164.36B | 49.78B |
| Q1 FY2016 | 31 Mar 2016 | 2.88 | 144.19B | 50.00B |
| Q4 FY2015 | 31 Dec 2015 | 3.41 | 171.70B | 50.39B |
| Q3 FY2015 | 30 Sept 2015 | 3.63 | 184.97B | 50.94B |
| Q2 FY2015 | 30 Jun 2015 | 3.84 | 198.95B | 51.75B |
| Q1 FY2015 | 31 Mar 2015 | 3.76 | 198.74B | 52.81B |
| Q4 FY2014 | 31 Dec 2014 | 3.48 | 186.67B | 53.63B |
| Q3 FY2014 | 30 Sept 2014 | 3.43 | 190.73B | 55.64B |
| Q2 FY2014 | 30 Jun 2014 | 3.34 | 184.50B | 55.25B |
| Q1 FY2014 | 31 Mar 2014 | 3.18 | 173.56B | 54.58B |
| Q4 FY2013 | 31 Dec 2013 | 2.93 | 163.55B | 55.76B |
| Q3 FY2013 | 30 Sept 2013 | 2.83 | 156.73B | 55.46B |
| Q2 FY2013 | 30 Jun 2013 | 2.57 | 145.44B | 56.59B |
| Q1 FY2013 | 31 Mar 2013 | 2.51 | 145.12B | 57.85B |
| Q4 FY2012 | 31 Dec 2012 | 2.23 | 128.16B | 57.56B |
| Q3 FY2012 | 30 Sept 2012 | 2.17 | 125.01B | 57.49B |
| Q2 FY2012 | 30 Jun 2012 | 1.94 | 113.23B | 58.48B |
| Q1 FY2012 | 31 Mar 2012 | 1.90 | 111.96B | 59.07B |
| Q4 FY2011 | 31 Dec 2011 | 1.94 | 115.08B | 59.38B |
| Q3 FY2011 | 30 Sept 2011 | 1.92 | 113.10B | 58.84B |
| Q2 FY2011 | 30 Jun 2011 | 2.17 | 122.66B | 56.63B |
| Q1 FY2011 | 31 Mar 2011 | 1.95 | 104.14B | 53.43B |
| Q4 FY2010 | 31 Dec 2010 | 2.19 | 112.85B | 51.56B |
| Q3 FY2010 | 30 Sept 2010 | 2.20 | 110.40B | 50.24B |
| Q2 FY2010 | 30 Jun 2010 | 1.90 | 92.49B | 48.71B |
| Q1 FY2010 | 31 Mar 2010 | 2.17 | 103.15B | 47.53B |
| Q4 FY2009 | 31 Dec 2009 | 2.29 | 103.29B | 45.10B |
| Q3 FY2009 | 30 Sept 2009 | 2.26 | 95.60B | 42.31B |
| Q2 FY2009 | 30 Jun 2009 | 1.84 | 77.25B | 42.05B |
| Q1 FY2009 | 31 Mar 2009 | 1.70 | 71.72B | 42.29B |
| Q4 FY2008 | 31 Dec 2008 | 2.21 | 94.20B | 42.58B |
| Q3 FY2008 | 30 Sept 2008 | 2.36 | 100.10B | 42.41B |
| Q2 FY2008 | 30 Jun 2008 | 2.53 | 104.39B | 41.20B |
| Q1 FY2008 | 31 Mar 2008 | 2.45 | 97.19B | 39.61B |
| Q4 FY2007 | 31 Dec 2007 | 2.67 | 103.46B | 38.76B |
| Q3 FY2007 | 30 Sept 2007 | 2.82 | 106.73B | 37.91B |
| Q2 FY2007 | 30 Jun 2007 | 2.96 | 109.71B | 37.12B |
| Q1 FY2007 | 31 Mar 2007 | 2.96 | 107.20B | 36.23B |
| Q4 FY2006 | 31 Dec 2006 | 3.22 | 112.82B | 35.00B |
| Q3 FY2006 | 30 Sept 2006 | 3.33 | 114.77B | 34.44B |
| Q2 FY2006 | 30 Jun 2006 | 3.12 | 105.83B | 33.90B |
| Q1 FY2006 | 31 Mar 2006 | 3.26 | 108.52B | 33.26B |
| Q4 FY2005 | 31 Dec 2005 | 3.16 | 102.55B | 32.45B |
| Q3 FY2005 | 30 Sept 2005 | 3.20 | 100.02B | 31.28B |
| Q2 FY2005 | 30 Jun 2005 | 3.10 | 92.46B | 29.85B |
| Q1 FY2005 | 31 Mar 2005 | 3.15 | 91.28B | 28.95B |
| Q4 FY2004 | 31 Dec 2004 | 3.65 | 103.19B | 28.25B |
| Q3 FY2004 | 30 Sept 2004 | 3.48 | 95.31B | 27.40B |
| Q2 FY2004 | 30 Jun 2004 | 3.44 | 91.47B | 26.55B |
| Q1 FY2004 | 31 Mar 2004 | 3.41 | 87.84B | 25.78B |
| Q4 FY2003 | 31 Dec 2003 | 3.83 | 95.13B | 24.86B |
| Q3 FY2003 | 30 Sept 2003 | 3.10 | 80.54B | 25.94B |
| Q2 FY2003 | 30 Jun 2003 | 3.32 | 82.34B | 24.79B |
| Q1 FY2003 | 31 Mar 2003 | 3.17 | 76.68B | 24.18B |
| Q4 FY2002 | 31 Dec 2002 | 3.26 | 76.13B | 23.32B |
| Q3 FY2002 | 30 Sept 2002 | 4.07 | 84.03B | 20.65B |
| Q2 FY2002 | 30 Jun 2002 | 4.34 | 91.84B | 21.17B |
| Q1 FY2002 | 31 Mar 2002 | 4.23 | 84.08B | 19.88B |
| Q4 FY2001 | 31 Dec 2001 | 4.00 | 77.94B | 19.47B |
| Q3 FY2001 | 30 Sept 2001 | 4.10 | 83.24B | 20.29B |
| Q2 FY2001 | 30 Jun 2001 | 3.99 | 78.26B | 19.59B |
| Q1 FY2001 | 31 Mar 2001 | 4.36 | 85.26B | 19.56B |
| Q4 FY2000 | 31 Dec 2000 | 4.77 | 99.39B | 20.82B |
| Q3 FY2000 | 30 Sept 2000 | — | 83.91B | — |
| Q2 FY2000 | 30 Jun 2000 | — | 85.46B | — |
| Q1 FY2000 | 31 Mar 2000 | — | 71.73B | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios
Common questions about Novartis's P/S ratio
Source: Financial Modeling Prep